Cargando…
Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment
Recently, technological advances in the detection and biological characterization of circulating tumor DNA (ctDNA) have enabled the implementation of liquid biopsy testing into clinical practice. Methods for analysis of liquid biopsies have rapidly evolved over the past few years and have continued...
Autor principal: | Sato, Yoshiharu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Exploration
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630093/ https://www.ncbi.nlm.nih.gov/pubmed/36338524 http://dx.doi.org/10.37349/etat.2022.00104 |
Ejemplares similares
-
Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer
por: Shen, Haifeng, et al.
Publicado: (2022) -
Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics
por: Guo, Matthew Z, et al.
Publicado: (2021) -
Liquid Biopsy in Non-Small Cell Lung Cancer
por: Molina-Vila, Miguel A., et al.
Publicado: (2016) -
Liquid biopsy genotyping in lung cancer: ready for clinical utility?
por: Huang, Wei-Lun, et al.
Publicado: (2017) -
Update on liquid biopsy in clinical management of non-small cell lung cancer
por: Wu, Zhen, et al.
Publicado: (2019)